SRTD biotech
Key Facts
| Invested since | 2024 |
| Based in | North Rhine-Westphalia |
About the company
SRTD biotech was founded in Jülich by Dr Bernd Hoffmann and Dr Heribert Bohlen. The aim of the biotech start-up is to develop highly efficient RNA-based drugs based on a proprietary platform technology. The team consists of experts in molecular biology, cell biology, chemistry, translational sciences and business development.
Do you want to
know more about this company?
SRTD biotech in the news
Zum Artikel
SRTD biotech secures seed financing: Side-effect freeRNA therapeutics active only in diseased cells
More startups from Life Sciences
CustomSurg, founded in 2021, is a Spin-Off from ETH Zurich and Harvard University. The company is developing software-as-a-medical-device (SaMD) solutions for the optimal selection and placement of orthopaedic implants in …
To the complete profileof CustomSurg
hema.to is an easy-to-use software for clinical decision support for blood cancer from cytometry data using AI. hema.to makes the diagnostic workflow both faster and better, helping both diagnosticians as …
To the complete profileof hema.to
Exit
KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare. Exit since Feb. 2011. Purchaser: Evotec AG
To the complete profileof KINAXO
Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.
To the complete profileof Cryotherapeutics
heartbeat ONE provides a streamlined patient management tool for health care facilities of all sizes. It offers intelligent evaluations of diagnostics and treatment methods. It supports the preparation, documentation and …
To the complete profileof heartbeat medical
Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer …
To the complete profileof Abalos
Exit
ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.
To the complete profileof ChromoTek
Exit
m2p-labs supplies microbioreactor systems focusing on micro fermentations and automated solutions for screening and bioprocess development. The product portfolio comprises high-throughput BioLector® micro fermentation systems, microtiter FlowerPlate® plates, and automated …
To the complete profileof m2p-labs
Coramaze Technologies develops an innovative, highly differentiated, transcatheter tricuspid valve repair system, called TriPair. Headquartered in Germany with an R&D hub in Israel, we promote health equity by offering a …
To the complete profileof coramaze
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …
To the complete profileof Lindis Blood Care
Umlaut.bio GmbH develops small molecules that are intended to be used as first-in-class therapeutics against a variety of diseases. The focus is on the “umlauts” of the genetic code – …
To the complete profileof Umlaut.bio
Ebenbuild is a health tech pioneer that creates personalized treatment recommendations for mechanical ventilation and ICU patient care for clinical users. Founded in Munich in 2019, the company develops software …
To the complete profileof Ebenbuild